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Abstract 40 
Introduction 
Excess aldosterone is associated with increased cardiovascular risk.  Aldosterone 
has a permissive effect on vascular fibrosis. Cardiovascular magnetic resonance 
imaging (CMR) allows study of vascular function by measuring aortic distensibility. 
We compared aortic distensibility in primary aldosteronism (PA), essential 
hypertension (EH) and normal controls and explored the relationship between aortic 
distensibility and pulse wave velocity (PWV).  
Methods We studied PA (n=14) and EH (n=33) subjects and age-matched healthy 
controls (n=17) with CMR, including measurement of aortic distensibility, and 
measured PWV using applanation tonometry. At recruitment, PA and EH patients 50 
had similar blood pressure and left ventricular mass.  
Results Subjects with PA had significantly lower aortic distensibilty and higher PWV 
compared to EH and healthy controls. These changes were independent of other 
factors associated with reduced aortic distensibility, including aging. There was a 
significant relationship between increasing aortic stiffness and age in keeping with 
physical and vascular aging. As expected, aortic distensibility and PWV were closely 
correlated.  
Conclusion These results demonstrate that PA patients display increased arterial 
stiffness compared to EH, independent of vascular aging. The implication is that 
aldosterone invokes functional impairment of arterial function. The long-term 60 
 4 
implications of arterial stiffening in aldosterone excess require further study. 
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Introduction 
The prevalence of Primary Aldosteronism (PA) is higher than previously thought. 
Aldosterone excess is found in approximately 10% of unselected hypertensives and 70 
up to 20% of subjects with resistant hypertension1, 2. It is known that PA patients are 
at increased cardiovascular risk in comparison to subjects with essential  
hypertension (EH) and equivalent blood pressure, including dramatic increases in 
risk of  cerebrovascular disease, myocardial infarction and prevalence of atrial 
fibrillation3. These observations and others suggest that aldosterone excess has 
significant adverse cardiovascular effects beyond its influence on blood pressure4, 5. 
One potential mechanism linking aldosterone and cardiovascular disease relates to 
arterial stiffness; in vitro data suggest that aldosterone stimulates hyperplasia of 
vascular smooth muscle cells and additionally activates protein synthesis, increasing 
extracellular matrix and collagen deposition, leading to vascular fibrosis6-8. Patients 80 
with PA have been demonstrated to have increased carotid intima media thickness 
at ultrasound compare to EH, suggesting aldosterone excess contributes the fibrosis 
and thickening of the arterial wall9. In addition, aldosterone has also been shown to 
adversely affect endothelial function by enhancing oxidative stress and 
inflammation10, 11.  The potential sequelae of these effects include increasing 
vascular stiffness and atherosclerosis, which may impede conduit arterial function 
and worsen cardiovascular outcome. 
Epidemiological studies have shown that increased arterial stiffness, most commonly 
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assessed by measurement of pulse wave velocity (PWV) is independently 
associated with cardiovascular risk factors and morbidity 12, 13. PWV, measured 90 
using applanation tonometry, is the ‘gold-standard’ technique of arterial stiffness 
assessment in human subjects although alternative methods have emerged14. A 
number of studies have demonstrated increased arterial stiffness or impaired arterial 
conduit function in PA patients compared to EH, using PWV or augmentation index 
(AIx), respectively, measured with applanation tonometry15, 16. Cardiovascular 
magnetic resonance imaging (CMR) permits visualisation of large arteries and 
potentially offers an integrated non-invasive method of assessing vascular, as well 
as ventricular function, during the same examination. Aortic distensibility (AD) is an 
index of arterial stiffness and can be defined as the relative change in the cross-
sectional area of the aorta divided by central pulse pressure. AD measured with 100 
CMR has emerged as a marker of vascular function in groups at elevated 
cardiovascular risk 17, 18. CMR allows direct visualisation of blood vessels and is 
independent of crude estimates of aortic length from tape measurements along the 
body surface, which are required for PWV assessment with tonometry. CMR also 
allows vascular assessment in subjects where tonometry may be challenging such 
as obese subjects.  
  
To date however, the relationship between AD, measured with CMR, and PWV has 
not been assessed in PA patients or compared with EH subjects. Thus, we assessed 
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the relationship between CMR measures of vascular function, PWV, AIx and 110 
conventional CV risk factors in recently diagnosed PA with EH patients and healthy 
controls. To give insight into the mechanistic basis for any observed differences we 
also measured markers of inflammation and oxidative stress in PA and EH groups. 
We hypothesised that PA subjects would exhibit a more adverse vascular phenotype 
in comparison to EH subjects using CMR. 
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Subjects and Methods 
Subjects 
Fourteen patients with confirmed PA diagnosed in the Endocrine Department, 
Western Infirmary, Glasgow were studied. All were diagnosed with PA using 120 
Endocrine Society guidelines19. Briefly, screened subjects with an elevated 
aldosterone to renin ratio (ARR) (> 750 with aldosterone in pmol/l and renin 
measured as plasma renin activity in ng/ml/hr; >35 if renin measured as plasma 
renin concentration in mIU/mL) underwent repeat screening after withdrawal of all 
treatment affecting measurements of plasma renin and aldosterone (for 4-6 weeks). 
If the elevated ARR persisted, then autonomous aldosterone excess was confirmed 
using a saline suppression test. In this test, PA is confirmed if plasma aldosterone is 
>270pmol/L despite infusion of 2 litres of normal saline over 4 hours. Subjects 
subsequently underwent adrenal imaging (computerised tomography or magnetic 
resonance imaging) and adrenal vein sampling if surgery was to be considered in 130 
order to differentiate between unilateral and bilateral forms of PA.  
  
Two control groups were studied.  Thirty-three patients with EH comprised the first 
group. All patients with PH had a normal ARR and none were on mineralocorticoid 
receptor (MR) antagonists. No patient had pre-existing structural cardiac 
abnormalities (excluded by clinical examination and echocardiography where 
appropriate). All subjects were out-patients with no inter-current illness at the time of 
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study.  A cohort of seventeen healthy volunteers with no past medical history and on 
no regular medication was also studied.  This study was approved by the West of 
Scotland Research Ethics Committee and all subjects gave informed consent. 140 
  
CMR technique 
All patients underwent CMR using a 1.5 Tesla MRI scanner (Sonata, Siemens, 
Erlangen, Germany. A fast-imaging with steady-state precession sequence was 
used to acquire cine images of the left ventricle (LV) in long axis followed by 
sequential short axis LV cine loops (8mm slice thickness, 2mm gap between slices) 
from the atrioventicular ring to the apex. Imaging parameters, which were 
standardized for all subjects, included:  TR/TE/flip angle/voxel size/FoV = 3.14 
ms/1.6 ms/60°/2.2 x 1.3 x 8.0 mm/340 mm. 
  150 
AD was assessed from cine MR images in the transverse plane of the ascending 
aorta were obtained at the level of the main pulmonary artery (Figure 1) utilising a 
fast-imaging with steady-state precession sequence (TR=3.2 ms, TE=1.6 ms, flip 
angle =60°, FoV 276x340mm, pixel dimensions 2.3x1.3mm, slice thickness=7 mm). 
The approximately 10 second breath-hold CMR sequence resulted in prospective 
images with a temporal resolution of at least 22.5ms. During image acquisition, blood 
pressure was measured in the CMR scanner using a non-ferromagnetic brachial 
artery sphygmomanometer cuff (Schiller instruments, Baar, Switzerland). 
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 LV mass was analysed short axis cine loops using tracing of epicardial and 
endocardial end-systolic and end-diastolic contours with LV mass calculated using 160 
analysis software (Argus, Siemens, Erlangen, Germany) and normalised to body 
surface area. Aortic distensibility was calculated as previously described from 
change in aortic volume and simultaneous brachial blood pressure acquired during 
the scan using the formula20, 21: 
  
Aortic 
distensibilty 
= 
[(Aortic volume)max - (Aortic volume)min] 
[(Aortic volume) min * pulse pressure] 
  
where (Aortic volume)max and (Aortic volume)min are the maximal and minimal 
calculated aortic volumes obtained during the cardiac cycle. A schematic illustration 
of the contour tracing the cross sectional aortic volume is shown in Figure 1. All CMR 
scans were anonymised with a code number prior to analyses performed by two 170 
observers (P.B.M., S.B.) blinded to the clinical characteristics of the subjects.  
 
Applanation tonometry measurement of pulse wave velocity 
Measurements of PWV and AIx were carried out after 15 min of rest in the supine 
position using the SphygmoCor® Vx system (Atcor Medical, Sydney, Australia). 
PWV was measured from sequentially recorded electrocardiogram-gated carotid, 
femoral artery waveforms. Timing of the pulse wave was using the intersecting 
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tangent algorithm with carotid-femoral pathway measured using the distance 
obtained by subtracting the carotid measurement site to sternal notch distance from 
the sternal notch to femoral measurement site distance. PWV measurements were 180 
made in triplicate, and the mean values were used in the subsequent analysis. AIx, a 
measure of wave reflection, was determined from radial waveforms using the same 
device and corrected to heart rate of 75 beats per minute.  A trained nurse (blinded 
to the clinical characteristics of the subjects) performed tonometry measurements. 
  
Blood sampling 
Venepuncture was performed in the PA and EH subjects for routine biochemistry on 
the day of scanning and analysed in the standard clinical laboratories at the Western 
infirmary, Glasgow. C-reactive protein (CRP) was measured in a single run on all 
samples using a high-sensitivity method on a clinically validated automated platform 190 
(c311, Roche Diagnostics, Burgess Hill, UK). The analyser was calibrated and 
quality controlled using the manufacturers reagents, and according to their 
instructions. Coefficient of variation of the QC was <5%. Plasma aldosterone was 
measured by direct radioimmunoassay (RIA) utilising the ‘Coat-A-Count’ system 
(Euro/DPC Ltd, Caernarfon,Wales). The radioisotope used was 125I aldosterone. 
Coefficients of variation (%, within-batch and between-batch respectively) were: 2.3–
5.4/3.8–15.7. 
Oxidative stress status was assessed by analysing superoxide release from whole 
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blood using an established method22, 23. In brief, venous blood was collected in 
lithium heparinate containing tubes, kept on ice and processed within half an hour. 200 
Superoxide levels were detected by electron paramagnetic resonance (e-scan R; 
Bruker BioSpin GmbH, Rheinstetten, Germany) with the spin probe 1-hydroxy-3-
carboxy-2,2,5,5-tetramethylpyrrolidine (CPH; Noxygen, Elzach, Germany) to a final 
concentration of 500 μM. Instrument settings were: centre field of 3375 G, 
modulation amplitude of 2.27 G, sweep time of 5.24 s, sweep width of 60 G and 10 
scans. Superoxide levels were recorded as counts per minute for 10 min and a best 
fit regression line through these data points was constructed; the calculated slope of 
this line was used to measure the rate of superoxide anion production. 
 
 Power calculation 210 
Based on our previous CMR studies of AD, if the true difference in the experimental 
and control means is 3 x 10-3 mmHg-1, 12 PA subjects and 24 EH controls are 
required to detect a significant difference between PA patients and EH patients with 
power 0.8 and type I error of 0.05.  
 
Statistical methods 
Differences between groups were tested by Chi-squared or Fisher’s exact test and 
appropriate for categorical variables and by Student’s t-test and Mann-Whitney-U 
test for continuous variables. Correlations between cardiac dimensions, measures of 
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arterial function and continuous clinical variables were assessed with the Pearson 220 
and Spearman correlation co-efficients. Analysis of covariance was used to assess 
influence of covariates on differences between groups. All analyses were performed 
using the SPSS 19.0 software package (IBM, Armonk, NY, USA). 
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Results 
Patient demographics, therapy and clinical variables 
Patient demographics and the various measures of vascular function are shown in 230 
Table 1. There were no significant differences in age, gender or left ventricular mass 
index between the three groups. Blood pressure was numerically but not significantly 
higher in the PA groups compared to EH. Predictably, the healthy control group had 
a significantly lower body mass index (BMI), systolic, diastolic and pulse pressure 
compared to both the PA and EH subjects. As expected, PA subjects had 
significantly higher plasma aldosterone levels than PH but there was no difference 
between plasma CRP or whole blood superoxide production between these subject 
groups. As the lab changed assays from plasma renin activity to plasma renin 
concentration during the study, data on renin levels are not presented.  
 240 
There were no significant difference in use of angiotensin converting enzyme 
inhibitors, angiotensin receptor antagonists, beta-blockers or calcium channel 
antagonists at the time of study between the PA and EH subjects. No PA patients 
were receiving thiazide diuretics, which were used in 21 (63.6%) of EH patients.  Of 
the 14 PA patients, four were on no specific therapy at the time of study, nine 
patients were receiving MR antagonists (seven on spironolactone, two on 
eplerenone) and one patient had undergone adrenalectomy seven months prior to 
study. In patients on MR antagonists the median duration of therapy was 180 days 
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(range 28-360 days). Therefore all PA subjects included in the study were 
investigated either before, or within one year, of either adrenalectomy or 250 
commencing specific medical therapy. 
 
 Left ventricular dimensions and function 
There were no significant differences between LV mass between PA and EH 
patients or controls, although LV mass was slightly higher in patients compared to 
controls. However, PA patients did have smaller LV end diastolic volume compared 
to both EH patients and controls. No group had evidence of LV systolic dysfunction. 
In fact, PA patients had significantly higher LV ejection fraction than either EH 
patients or controls (Table 2).  
 260 
Measures of vascular function 
AD was significantly lower in both PA and EH compared to healthy controls 
(p<0.001), with AD additionally being significantly lower in PA compared to EH 
subjects despite similar ages and blood pressures in the groups (Figure 2). There 
was a significant negative correlation between age and AD in the whole cohort of 
patients (R= -0.454, p<0.001, Figure 3). Both markers of increased aortic stiffness 
correlated with increasing BMI (AD R= -0.277, p=0.028; PWV R= 0.295, p=0.022). 
There were no significant correlations between AD and plasma aldosterone levels, 
any lipid parameter, C-reactive protein, IL-6, superoxide, calcium or phosphate. 
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There were no significant differences in AD between genders in PA or EH groups 270 
although AD was lower in male healthy controls compared to females (mean AD 3.9 
x 10-3 vs. 5.2 x10-3, p=0.055) despite similar blood pressures.  However, the number 
of females in the PA and EH groups was small. 
Heart rate-corrected central AIx was significantly lower in the healthy controls 
compared to EH patients, with a trend towards being lower in PA patients. There was 
no significant difference in AIx between PA and EH subjects and there did not 
appear to be any significant relationship between AIx and any clinical variables other 
than blood pressure (see below).  
 
Analysis of covariance performed to assess the differences in AD between the 280 
groups independent of age as a covariate, confirmed significantly lower AD in PA 
and EH patients compared to controls as a reference. Additionally this demonstrated 
that, for every increase in age by one year, AD reduces by 6.75 x 10-5 Hg-1, 
irrespective of the effect of patient group (Table 3). By contrast PA subjects have a 
reduction of 1.0 x 10-3Hg-1 compared to PH patients; therefore essentially, PA 
conveys an excess equivalent of 14.8 years additional aging compared to EH with 
comparable blood pressure.  Figure 4 illustrates that PWV was significantly higher in 
both PA and EH compared to controls (p<0.001), with PWV additionally being 
significantly higher in PA compared to EH subjects (p=0.001) 
  290 
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Relationship between measures of vascular function 
As would be expected for complementary methods of assessment of vascular 
function, there was a significant correlation between AD and PWV (R -0.433, 
p<0.001, Figure 5). There were also significant correlations between most blood 
pressure variables and both AD and PWV. The Spearman correlation co-efficient for 
AD and blood pressure variables were as follows; systolic blood pressure (R -0.533, 
p<0.001), diastolic blood pressure (R -0.230, p=0.067) and pulse pressure (R -0.540, 
p<0.001). The Spearman correlation co-efficient for PWV and blood pressure 
variables were as follows; systolic blood pressure (R 0.317, p=0.013), diastolic blood 
pressure (R 0.297, p=0.02) and pulse pressure (R 0.245, p=0.057). AIx correlated 300 
significantly with AD (Spearman R -0.378, p=0.002), systolic blood pressure (R 
0.426, p<0.001) and pulse pressure (R 0.407, p=0.001) but not diastolic blood 
pressure or PWV.  
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Discussion 
In this study, PA is associated with increased aortic stiffness manifest as reduced 
aortic distensibility (AD) and higher pulse wave velocity compared to both healthy 
controls and subjects with EH. This finding persists after adjustment for age, the 310 
other significant predictor of AD. These findings offer further insights into 
mechanisms involved in blood-pressure independent increased cardiovascular risk 
associated with aldosterone excess. Importantly, this is the first study to use CMR to 
assess AD in PA subjects, although this well-validated technique has been used to 
explore vascular morbidity in other populations at increased cardiovascular risk17, 18.  
  
Our findings that PWV is increased in PA subjects compared to EH and 
normotensive cohorts, confirm findings of other similar studies15, 24. Central PWV is 
an established method for assessment of central arterial compliance, with higher 
PWV being a marker of stiffer central vessels. In vitro and animal studies have 320 
demonstrated that aldosterone-mediated MR activation leads directly to vascular 
smooth muscle cells proliferation and excess collagen deposition resulting in 
vascular remodelling and fibrosis 10, 11. In addition, longer term clinical studies have 
demonstrated that amelioration of aldosterone excess either by adrenalectomy or 
MR blockade reduces PWV as well as carotid intima medial thickness (a surrogate 
marker of atherosclerosis) at one year following treatment16, 25.  
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In addition to the observation that AD is reduced in PA subjects compared to other 
groups, a significant correlation was observed between AD and both age and PWV. 
The correlation between AD and age across the groups reflects increasing severity 330 
of arteriosclerosis with age which persists irrespective of the study group26.  The 
observed correlation between PWV and AD (as well as the correlation between AD 
and AIx), to an extent demonstrates a validation of both techniques as measures of 
arterial stiffness.  
 
There were no differences in left ventricular masses between the groups (all of which 
were in the normal range) despite suboptimal blood pressure control in both the PA 
and EH patients. We were very surprised not to find higher LV mass in the PA 
population particularly compared to healthy controls, although the mean LV mass in 
controls was a little lower. This probably reflects the fact that participants had been 340 
screened to exclude significant cardiac abnormalities prior to participation. This may 
reflect relatively ‘mild’ hypertension demonstrated by the PA patients in this study as 
some patients had commenced specific therapy, which may have already begun to 
induce regression of LV hypertrophy. The implication from our results is that 
impairment of vascular function occurs earlier in the course of PA, prior to the onset 
of left ventricular hypertrophy as end organ damage and may regress more slowly. 
Additionally, most other studies of LV dimensions in PA and hypertensive patients 
rely on echocardiography data; CMR provides a more sensitive method of structural 
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analysis and it is unclear how well CMR and echocardiographic findings correlate. In 
one previous study, LVH using CMR was found in only 83 of 440 subjects (18%) with 350 
pre-identified LVH using echocardiography27. It is also significant that in the only 
other study using relating aldosterone status with CMR findings, there was no 
significant difference in LVMI between EH subjects with high versus low aldosterone 
production28. The higher LV ejection fraction and smaller LV end systolic volume in 
the PA group is intriguing and contrasts with a recent echocardiographic study, 
which showed the reverse with larger LV end systolic and end diastolic volumes in 
PA patients29. We speculate that in our study, the small end systolic volume may 
lead to impaired LV filling and may be a risk factor for diastolic dysfunction and/or 
heart failure with preserved ejection fraction. We were surprised that there were no 
differences in oxidative stress or C-reactive protein between groups, although this 360 
may simply reflect the relatively small size of the groups as excess aldosterone has 
been associated with both oxidative stress and inflammation 30.  
  
 AD has been utilised in several other patient groups as either a marker of increased 
vascular risk or for identifying patients at risk of poorer long term cardiovascular 
survival21. In otherwise healthy young individuals, obese subjects have been shown 
by CMR to have decreased aortic compliance31. We observed a significant 
correlation between increasing BMI and reduced AD and PWV in our cohort. AD has 
been demonstrated to be reduced in heart failure18, ischaemic heart disease, end 
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stage renal disease17, and diabetes32. AD may represent a surrogate marker for 370 
clinical trials and has been shown to improve following significant weight loss in 
obese subjects33.  Interestingly in patients with chronic kidney disease, the addition 
of spironolactone to conventional antihypertensive therapy improved AD significantly 
compared to placebo, hinting at beneficial effects of MR antagonism on the 
vasculature in a non-PA patient cohort34.  
 
Our study has some limitations. As a cross sectional study, our study demonstrates 
an association between increased PA and increased arterial stiffness and do not 
imply causation. The size of the overall cohort is relatively small, as is each of the 
individual subgroups. Despite our aim to match the hypertensive groups, blood 380 
pressure was higher in the PA group, which may have some bearing on the results 
of vascular function studies. Despite our attempts to match the groups as much as 
possible for factors which may influence AD (age, renal function, BMI), with this 
small study it is possible that other unrecognised factors may influence AD across 
the groups. Measurement of brachial rather than central blood pressure is a potential 
issue when using AD as a marker of vascular stiffness.  Calculation of AD is based 
on cross-sectional volume of the vessel wall and pulse pressure. For practical 
reasons, direct aortic blood pressure measurement has been substituted by non-
invasive indirect brachial blood pressure measurement. Therefore it is difficult to 
dissociate any clinical effect associated with changes in aortic distensibilty from that 390 
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due directly to pulse pressure. Nonetheless, as it is otherwise impossible to truly 
assess aortic stiffness, without documentation of pressure within the vessel lumen, 
the approach used in this study has been used widely in other patient groups. 
Finally, whilst CMR is becoming an increasing widely used technique, it remains 
expensive and time consuming, and currently remains established as a research tool 
rather than as routine clinical measure of vascular health. The major advantage of 
using CMR over other imaging modalities, is its ability to provide comprehensive 
assessment of the vasculature and detailed analysis of myocardial tissue 
composition in patients at elevated cardiovascular risk in one examination without 
the use of ionising radiation35. Progress is still required to facilitate more rapid 400 
scanning and analysis at lower cost. Better automated analysis software should 
facilitate straightforward assessment of the acquired images. 
  
In summary, these results demonstrate that PA patients demonstrate increased 
arterial stiffness compared to comparable degrees of EH, independent of normal 
vascular aging. This has been illustrated using both applanation tonometry and, 
uniquely, by assessment of aortic distensibility using CMR.  The implication is that 
aldosterone per se rather than subsequent hypertension invokes arterial remodelling 
by direct effects on vascular smooth muscle cells leading to functional impairment of 
arterial conduit function. Both CMR and PWV are potential surrogate markers of 410 
vascular health, which may represent targets for clinical trials of interventions in PA 
 23 
patients. The long-term prognostic implications of increased arterial stiffening in 
association with aldosterone excess require further study. 
  
 
Acknowledgements  
The authors acknowledge the work of Tracey Steedman and Kirsten Lanaghan in 
performing cardiac MRI imaging. PBM is funded by Syskid European Union's FP7, 
Grant agreement number HEALTH–F2–2009–241544. EMF is funded by a Clinician 
Scientist Fellowship awarded by the Medical Research Council (reference number 420 
G0802803). This study was supported by the European Union's Seventh Framework 
Programme "EU-MASCARA" and the British Heart Foundation Programme Grant 
RG/07/005/23633 
 
Conflict of Interest. The authors have no conflicts of interest to declare.  
  
 24 
Summary Table 
 
What is known about the topic 
 
• Excess aldosterone is associated with increased cardiovascular risk 
 
• Cardiovascular magnetic resonance imaging (CMR) is a novel tool for 
studying vascular function by measuring aortic distensibility 
 
• Patients with primary aldosteronism (PA) have been shown to have 
increased arterial stiffness measured by pulse wave velocity. This may 
improve after adrenalectomy in adenomatous PA 
 
What this study adds 
 
• PA patients displayed increased arterial stiffness with both CMR and PWV 
compared to comparable degrees of essential hypertension, independent of 
aging 
 
• The long term implications of increased arterial stiffening in association with 
aldosterone excess require further study 
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Legend  430 
Table 1. Demographics and clinical data of the subjects. Values are mean plus 
standard deviation in parentheses for all values except gender and diabetes where 
number and percentage are shown, duration of hypertension where median and 
inter-quartile range is shown and number of antihypertensives where median and 
range are displayed. Tests of significance for non-categorical variables are t-test 
except duration of hypertension, plasma aldosterone and number of AHT where 
Mann-Whitney U is used. Abbreviations- BMI- body mass index, SBP- systolic blood 
pressure; DBP- diastolic blood pressure, LDL –low density lipoprotein; CRP - C –
reactive protein; eGFR – estimated glomerular filtration rate by 4 variable MDRD 
formula; AHT – antihypertensives; BSA- body surface area;  A.u. Arbitary units.  * 440 
p<0.05 PA vs. EH, † p<0.001 PA vs. EH, ‡ p<0.01 Controls vs. PA/EH subjects, § 
p<0.001 Controls vs. PA/EH subjects 
Table 2 
Results of vascular function and left ventricular dimensions and function. 
Abbreviations- * p<0.05 PA vs. EH, † p<0.001 PA vs. EH, ‡ p<0.01 Controls vs. 
PA/EH subjects, § p<0.001 Controls vs. PA/EH subjects, || p<0.05 Controls vs. EH 
subjects, # p<0.01 Controls vs. PA subjects, ** p<0.05 Controls vs. PA subjects 
Table 3 
 Results of analysis of covariance. β represents differences between mean AD 
between groups for PA and EH groups compared to healthy volunteers as the 450 
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reference, and the relative effect of age on AD when clinical group is controlled as a 
covariate. 
Figure 1. Schematic diagram of the cross sectional aortic area being defined 
(volume is calculated by multiplication by the CMR slice thickness). AA- ascending 
aorta, DA- descending aorta 
 Figure 2. Box and whisker plots of AD in groups. The central line represents the 
median with the boxes representing the 25th and 75th percentiles. The whiskers 
represent 95% confidence intervals for normally distributed data. The open circles 
are outlying subjects.  
Figure 3. Scatter plot of AD vs. age. R2 is for Pearson correlation co-efficient 460 
Figure 4. Box and whisker plots of PWV by groups. Format is as per Figure 2  
Figure 5. Scatter plot of AD vs. PWV. R2 is for Pearson correlation co-efficient 
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Figure 2 470 
 29 
 
Figure 3 
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Figure 4 
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Figure 5 480 
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  PA  EH  Controls  
Number 14  33  17  
Age 58.4 (11.6) 54.8 (9.1) 51.8 (8.2) 
Male (%) 11 (78.6) 28 (84.8) 10 (58.8) 
BMI 29.8 (4.3) 29.1 (4.4) 25.8‡ (3.7) 
Diabetes (%) 1 (7.1) 2 (6.1) 0  
SBP (mmHg) 152.9 (30.7) 145.8 (16.3) 117.1§ (10.4) 
DBP (mmHg) 92.3 (11.6) 89.2 (8.6) 74.4§ (7.5) 
Pulse pressure (mmHg) 60.6 (26.9) 56.6 (15.2) 42.8‡ (6.2) 
Duration of hypertension (years) 7.5 (15.0) 10 (13.8) - - 
Sodium (mmol l-1) 140.5 (2.7) 139.5 (2.0) - - 
Potassium (mmol l-1) 3.6* (0.7) 3.9 (0.4) - - 
eGFR (ml min-11.73m-2) 85.7 (13.4) 95.1 (18.9) - - 
LDL cholesterol (mmol l-1) 2.1 (0.2) 2.9 (0.9) - - 
CRP (mg l-1) 2.4 (1.7) 2.3 (2.3) - - 
Number of AHT 2.5 (1-4) 2 (0-5) - - 
Plasma aldosterone(pmol l-1) 734.2† (311.0) 311.5 (251.1) - - 
Oxidative stress (A.u.) 0.44 0.20 0.42 0.25 - - 
Table 1
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  PA  EH  Controls  
PWV (m s-1) 10.3† (2.1) 7.7 (2.3) 6.4‡ (1.3) 
Augmentation Index (%)  27.1 (5.7) 28.2 (6.8) 22.2|| (8.2) 
AD  (x 10-3 mmHg-1) 1.9* (1.0) 3.1 (1.9) 4.4§ 1.3 
LV Mass/BSA (g m-2) 65.2. (11.6) 65.0 (17.2) 64.6 (13.1) 
End diastolic volume/BSA (ml m-2)  59.9 (11.1) 65.8 (12.3) - - 
End systolic volume/BSA (ml m-2)  14.6* (6.2) 21.0 (9.4) - - 
Ejection fraction (%) 76.1* (6.1) 68.8 (10.7) - - 
 
Table 2 
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  β 95% Confidence Interval for β p 
     
Intercept 0.008 (0.006,  0.010) 0.000 
Age -6.752 x 10-5 (0.000, -2.745 x 10-5) 0.001 
PA -0.002 (-0.003, -0.001) 0.000 
EH -0.001 (-0.002, 0.000) 0.010 
Controls Reference  - 
    
 490 
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